Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

NCT03562507 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Lack of patient population

Conditions

Renal Cell Carcinoma, Metastatic

Interventions

DRUG: ESK981
DRUG: Nivolumab

Sponsor

University of Michigan Rogel Cancer Center